Literature DB >> 19966593

Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.

Brian W Morrison1, Nicole A Doudican, Kirtesh R Patel, Seth J Orlow.   

Abstract

Melanoma is the most aggressive and deadly form of skin cancer. The current standard of care produces response rates of less than 20%, underscoring the critical need for identification of new effective, nontoxic therapies. Disulfiram (DSF) was identified using a drug screen as one of the several compounds that preferentially decreased proliferation in multiple melanoma subtypes compared with benign melanocytes. DSF, a member of the dithiocarbamate family, is a copper (Cu) chelator, and Cu has been shown previously to enhance DSF-mediated growth inhibition and apoptosis in cancer cells. Here, we report that in the presence of free Cu, DSF inhibits cellular proliferation and induces apoptosis in a panel of cell lines representing primary and metastatic nodular and superficial spreading melanoma. Both decreased cellular proliferation and increased apoptosis were seen at 50-500 nmol/l DSF concentrations that are achievable through oral dosing of the medication. In the presence of Cu, DSF caused activation of the extrinsic pathway of apoptosis as measured by caspase-8 cleavage. The addition of Z-IETD-FMK, a selective caspase-8 inhibitor, was protective against DSF-Cu-induced apoptosis. Production of reactive oxygen species (ROS) in response to DSF-Cu treatment preceded the induction of apoptosis. Both ROS production and apoptosis were prevented by coincubation of N-acetyl cysteine, a free radical scavenger. Our study shows that DSF might be used to target both nodular and superficial spreading melanoma through ROS production and activation of the extrinsic pathway of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19966593     DOI: 10.1097/CMR.0b013e328334131d

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  30 in total

1.  Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.

Authors:  Subha Bakthavatsalam; Mark L Sleeper; Azim Dharani; Daniel J George; Tian Zhang; Katherine J Franz
Journal:  Angew Chem Int Ed Engl       Date:  2018-08-29       Impact factor: 15.336

Review 2.  Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.

Authors:  Maricela Viola-Rhenals; Kush R Patel; Laura Jaimes-Santamaria; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Curr Med Chem       Date:  2018-02-12       Impact factor: 4.530

Review 3.  Ovarian cancer stem cell markers: prognostic and therapeutic implications.

Authors:  Daniela Burgos-Ojeda; Bo R Rueda; Ronald J Buckanovich
Journal:  Cancer Lett       Date:  2012-02-11       Impact factor: 8.679

4.  A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.

Authors:  Ilana Chefetz; Edward Grimley; Kun Yang; Linda Hong; Ekaterina V Vinogradova; Radu Suciu; Ilya Kovalenko; David Karnak; Cynthia A Morgan; Mikhail Chtcherbinine; Cameron Buchman; Brandt Huddle; Scott Barraza; Meredith Morgan; Kara A Bernstein; Euisik Yoon; David B Lombard; Andrea Bild; Geeta Mehta; Iris Romero; Chun-Yi Chiang; Charles Landen; Benjamin Cravatt; Thomas D Hurley; Scott D Larsen; Ronald J Buckanovich
Journal:  Cell Rep       Date:  2019-03-12       Impact factor: 9.423

5.  Copper signaling axis as a target for prostate cancer therapeutics.

Authors:  Rachid Safi; Erik R Nelson; Satish K Chitneni; Katherine J Franz; Daniel J George; Michael R Zalutsky; Donald P McDonnell
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

6.  Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.

Authors:  Alex G Peniche; Adam R Renslo; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 7.  Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.

Authors:  Muhammad Asim Farooq; Md Aquib; Daulat Haleem Khan; Zahid Hussain; Anam Ahsan; Mirza Muhammad Faran Ashraf Baig; Dickson Pius Wande; Muhammad Masood Ahmad; Hafiz Muhammad Ahsan; Jiang Jiajie; Bo Wang
Journal:  Daru       Date:  2019-11-22       Impact factor: 3.117

8.  A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.

Authors:  Kristen C Kelley; Kenneth F Grossman; Mary Brittain-Blankenship; Kelli M Thorne; Wallace L Akerley; Moises C Terrazas; Ken M Kosak; Kenneth M Boucher; Saundra S Buys; Kimberly A McGregor; Theresa L Werner; Neeraj Agarwal; John R Weis; Sunil Sharma; John H Ward; Thomas P Kennedy; Douglas W Sborov; Paul J Shami
Journal:  BMC Cancer       Date:  2021-05-07       Impact factor: 4.430

9.  Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.

Authors:  Kirsi Ketola; Olli Kallioniemi; Kristiina Iljin
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

Review 10.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.